Cybin files 13th provisional patent application focused on building up its telemedicine capabilities

Cybin (CYBN.NE) announced it has filed their 13th provisional patent application and is building out its digital therapeutics strategy.

Related Posts

Cybin: Researching Psychedelic Therapies for a Variety of Issues Using a Range of Delivery Methods

Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering

VIDEO: Cybin (CYBN.NE) Completes 51st Pre-Clinical Psychedelic Molecule Study

VIDEO: Cybin (CYBN.NE) selects SAD and GAD as targets for their CYB004 psychedelic molecule

VIDEO: Cybin (CYBN.NE) files international patent application with Patent Cooperation Treaty (PCT)

VIDEO: Cybin (CYBN.NE) receives approval from IRB for CYB001 Phase II clinical trial

More on CYBN.NE

Cybin: Researching Psychedelic Therapies for a Variety of Issues Using a Range of Delivery Methods

Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering

VIDEO: Cybin (CYBN.NE) Completes 51st Pre-Clinical Psychedelic Molecule Study

VIDEO: Cybin (CYBN.NE) selects SAD and GAD as targets for their CYB004 psychedelic molecule

VIDEO: Cybin (CYBN.NE) files international patent application with Patent Cooperation Treaty (PCT)

VIDEO: Cybin (CYBN.NE) receives approval from IRB for CYB001 Phase II clinical trial